{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dichlorphenamide
to a specific field?
There is one exact (name or code) match for dichlorphenamide
Status:
US Approved Rx
(2022)
Source:
ANDA215924
(2022)
Source URL:
First approved in 1958
Source:
NDA011366
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.
Showing 1 - 8 of 8 results
Status:
US Approved Rx
(2022)
Source:
ANDA215924
(2022)
Source URL:
First approved in 1958
Source:
NDA011366
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Diclorphenamide, a carbonic anhydrase inhibitor, was initially developed for the treatment of glaucome, however, now it is used for patients suffering from primary hypokalemic and hyperkalemic periodic paralysis. The exact mechanism of diclorphenamide in periodic paralysis is unknown.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Antibacterial Hand Sanitizer by Shanghai Rayshine ENVI-TECH Developing CO., Ltd.
(2020)
Source URL:
First approved in 2020
Source:
Antibacterial Hand Sanitizer by Shanghai Rayshine ENVI-TECH Developing CO., Ltd.
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2020)
Source:
ANDA209406
(2020)
Source URL:
First approved in 1998
Source:
NDA020816
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Brinzolamide reduces the amount of fluid in the eye, which decreases pressure inside the eye. Brinzolamide is a carbonic anhydrase inhibitor that is FDA approved for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Common adverse reactions include abnormal taste in mouth and blurred vision. The concomitant administration of brinzolamide and oral carbonic anhydrase inhibitors is not recommended. Plus, in patients treated with oral carbonic anhydrase inhibitors, rare instances of acid-base alterations have occurred with high-dose salicylate therapy.
